

PART I:

Personal Information:

Name: **Khaled Alhoms, D.Ph., Ph.D., M.S.**

Date of Birth: December 07, 1974

Nationality: Syrian and USA citizen

Marital Status: Married to Ghalia Alkatan (Syrian and USA citizen)

Children: Three: 1 Male: Yazen, 2 Females: Zenah and Ayah (Syrian and USA citizen)

Contact Information:

Office address: U.S.A: Quality HealthCare
7 Austin Street
Boston, MA. 02129
Syria: Alhoms Medical Laboratories
6 Aljalaa Abo Rumanah Main
Street, against Saudi Embassy)
Abo Romanah, Damascus

Home address: U.S.A: 73 Bellevue Hill Road
Boston, MA. 02132
Syria: 6 Saleem Aljazaeri Street
Abo Romanah, Next to American Embassy
Damascus

Home Tel: U.S.A: 001(617) 323-3390
Syria: 011(963)11 3337103
011(963)11 3353007

Mobile: U.S.A: 001(857) 222-3392
Syria: 011(963) 944270444
011(963) 967142000

Work Tel: U.S.A: 001(617) 242-9200
Syria: 011(963)11 3313401
011(963)11 3313433
011(963)11 3313440

Work Fax: U.S.A: 001(617) 242-9204
Syria: 011(963)11 3341539

E-Mail: kalhomsisi2002@gmail.com
kalhomsisi2002@yahoo.com
k.a.foph@aspu.edu.sy

Education:

- Harvard Medical School and Massachusetts General Hospital, Division of Laboratory Medicine, Department of Clinical Pathology, Boston, USA
Post-Doctoral Fellowship Training in Clinical Laboratories, 2006-2010
- Northeastern University and Massachusetts General Hospital, Harvard Medical School, Department of Biomedical Sciences, Boston, USA
Doctor of Philosophy (Ph.D.), 2002-2005
- Northeastern University, Bouvé College of Health Sciences, Department of Medical Laboratory Sciences, Boston, USA
Master of Science (M.S.), 2000-2002
- Northeastern University and Boston Medical Center, Department of Medical Laboratory Sciences, Clinical Hematology Laboratory, Boston, USA
Post-Graduate Certificate in Clinical Hematology, 1998-2002
- Damascus University, School of Pharmacy, Damascus, Syria
Doctor in Pharmacy and Pharmaceutical Chemistry Degree (Laboratory Diagnosis Specialty), 1993-1998

Professional Training and Experience:

2021 – now	Vice President Scientific Research Council Al-Sham Private University (ASPU), Syria
2019 - 2020	Vice Dean for Scientific Research Affairs Faculty of Pharmacy, Al-Sham Private University (ASPU), Syria
2010-now	Medical Laboratory Director and Owner Alhomsisi Clinical Laboratories, Abo Rumanah Main St., Damascus, Syria
2007- 2009	Research Fellow for Laboratory Assays Validation (Hemostasis and Thrombosis), Instrumentation Laboratory, Lexington, USA

- 2007- 2009 Clinical Fellowship (Clinical Chemistry, Immunochemistry).
Evaluate new assays in detecting tumors and cancers
Massachusetts General Hospital and Harvard Medical School,
Boston, USA

- 2007- 2008 Clinical Fellowship (Clinical and Special Coagulation Laboratory)
Massachusetts General Hospital and Harvard Medical School,
Boston, USA

- 2006-2007 Postdoctoral Fellowship Training, Division of Laboratory Medicine,
Department of Clinical Pathology, Massachusetts General Hospital
and Harvard Medical School, Boston, USA

- 2002-2005 Ph. D. Clinical Research, Division of Laboratory Medicine,
Department of Pathology (Ph.D. level), Massachusetts General
Hospital and Harvard Medical School, Boston, USA

- 2002 Clinical Internship, Division of Laboratory Medicine, Department of
Pathology, Clinical Hematology Laboratory, Boston Medical Center
and Boston University, Boston, USA

- 1998-2002 Post-Baccalaureate Certificate in Clinical Hematology, Department of
Medical Laboratory Sciences, Northeastern University, Boston, USA

- 1996-1997 Clinical Internship, Department of Laboratory Medicine, Tawleed
University Hospital, Damascus, Syria

Licensure and Certification:

- 2019 Faculty Member, Ministry of education, Damascus, Syria

- 2018 International Computer Driving License, ICDL

- 2016 Syrian Board, Laboratory Medicine, Syrian Commission for Medical
Specialties

- 2006 Laboratory Diagnosis Specialist, Syrian Clinical Laboratory Association
(SCLA), Syria

- 2006 License in Laboratory Diagnosis, Ministry of Health, Syria

- 2003 Hematology Specialist, Syrian Clinical Laboratory Association (SCLA),
Syria

- 2004 License in Hematology, Ministry of Health, Syria
- 2002 Board Registered (ASCP) in Hematology, USA

Professional Societies:

- 2008 Academy of Clinical Laboratory Physicians and Scientists (ACLPS), associate member
- 2007 The Endocrine Society (TES), associate member
- 2006 American Diabetes Association (ADA), professional member
- 2006 Society of Critical Care Medicine (SCCM), professional member
- 2006 The International Society on Thrombosis and Hemostasis (ISTH), associate member
- 2006 Society for Experimental Biology and Medicine (SEBM), associate member
- 2006 American Physiological Society (APS), regular member
- 2005 American Association of Bioanalysts (AAB), associate member
- 2005 American Society of Parasitologists (ASP), associate member
- 2005 American Association of Clinical Endocrinologists (AACE), professional member
- 2005 American Association of Reproductive Immunology (AARI), professional member
- 2004 American Association of Clinical Chemistry (AACC), associate member
- 2004 American Society of Clinical Laboratory Science (ASCLS), professional member
- 2004 American Society of Microbiology (AMS), active member
- 2004 Clinical Laboratory Management Association (CLMA), associate member
- 2003 American Association of Pharmaceutical Scientists (AAPS), associate member
- 2003 Syrian Clinical Laboratory Association (SCLA), associate member
- 2002 American Society of Clinical Pathology (ASCP), associate member
- 2001 Syrian Association of Pharmacy (SAP), associate member
- 1998 American Association of Pharmacy (AAP), associate member

PART II:

Research, Teaching, and Clinical Contributions:

Research:

- 2019- now : Al-Sham Private University, Lattakia, Syria
Do multiple scientific investigations in different medical areas
- 2017-2018: Almujtahed Hospital, Damascus, Syria
Study incoming cases to the emergency rooms and clinical laboratories during the Syrian crisis
- 2012-2016: Shriners Hospital for Burns, Boston, USA
Develop new techniques in Medical Microbiology system
- 2005-2008: Harvard Medical School and Massachusetts General Hospital, Division of Laboratory Medicine, Department of Pathology, Boston, USA
Develop and validate new assays in the clinical laboratory system
- 2002-2005: Harvard Medical School and Massachusetts General Hospital, Division of Laboratory Medicine, Department of Pathology, Boston, USA
Investigate the impaired immunity in alcoholics. It was based on studying the nonoxidative metabolites of ethanol, Fatty Acid Ethyl Esters (FAEE) in human mononuclear cells, and their role as mediators of ethanol-induced immunosuppression

Brief Description of Clinical Research Experience:

- Cell Culture
- Cell Isolation and Preparation for Study
- Thin Layer Chromatography (TLC) for Lipid Isolation and Quantitation
- GC-MS (Gas Chromatography- Mass-Spectrometry)
- Radiolabeling and Measuring Radioactivity by Liquid Scintillation Counter
- ELISA Studies (cAMP, Cytokines, ...)
- Hemacytometer for Cell Counting.
- Spectrofluorimeter (Calcium measurement)
- Spectrophotometer
- Automated Blood Count (CBC) and Cell Differentials
- Complete Coagulation Testing
- Clinical Chemistry, Immunodiagnostic panel testing

- Urine and Stool Testings
- Calibration
- QC (Quality Control)
- PCR (RT)

Research Certification:

- Certificate of Completion of the Partners Health Care System human-subject protection education requirements (Partners health Care, Boston, USA)
- Radiation Safety: using radioactive materials ^{14}C and ^3H (Massachusetts General Hospital, Boston, USA)
- Biological Safety: dealing with human blood and substances (Massachusetts General Hospital, Boston, USA)

Teaching:

- Al-Sham Private University, Faculty of Pharmacy
Department of Biochemistry, Lattakia and
Damascus, Syria
2019- now
- Northeastern University, Bouvé College of Health Sciences
Department of Medical Laboratory Sciences, Boston, USA
2005- 2009
Lecturer and laboratory supervisor
- Massachusetts General Hospital and Harvard Medical School, Division of
Laboratory Medicine, Department of Pathology, Boston, USA
2005-2009
Lecturer

Clinical Contributions:

- 2005-2009 Massachusetts General Hospital and Harvard Medical School,
Division of Laboratory Medicine, Department of Pathology.
Evaluate new versus current quantitative assays.
Develop screening and automated quantitative assays.

Seminars, Professional Meetings, Continuing Education and Conferences:

- Damascus University and Faculty of Medicine, Research Articles Methodology
March 26-28, 2023 Damascus University, Damascus, Syria
- Al-Moasat university Hospital, Latest Development in Laboratory Medicine
Diagnosis June 19-22, 2022 Dama Rose Hotel, Damascus, Syria
- Damascus University and Faculty of Medicine, Latest Development in Medicine
June 26-28, 2019 Dama Rose Hotel, Damascus, Syria
- Syrian Clinical Laboratory Association, Damascus Laboratory workshop and
scientific conference
January 24 -26, 2017 Damascus Sheraton Hotel, Syria
- American Society for Clinical Pathology (ASCP), workshops for laboratory
professionals
Update in flow cytometry and enhancing diagnostic skills in morphologic
hematology
October 30- November 01 2015, Springfield Marriott hotel, Springfield,
Massachusetts, USA
- American Diabetes Association (ADA), 5th annual healthcare professionals
luncheon
New Treatments for Diabetes: The Role of Incretin-Based Therapies
March 17th 2013, Seaport World Trade Center, Boston, USA
- American Association of Clinical Endocrinologists (AACE) meeting
Thyroid and parathyroid glands
November 17-18, 2011, O'keefe Auditorium Massachusetts General Hospital,
Boston, USA
- Northeastern University, Bouvé College of Pharmacy and Health Sciences
Department of Medical Laboratory Sciences
CellaVision seminar, digital microscopy: the new advanced technology in clinical
hematology
October 24, 2010, Curry Student Center, Boston, USA
- The American Diabetes Association consensus conference
IFG (Impaired Fasting Glucose) and IGT (Impaired Glucose Tolerance):
implications for diabetes care
October 16, 2009, Hilton O'Hare International Airport, Chicago, USA
- The American Society for Microbiology (ASM) 106th general meeting
Addressing management issues
New technologies by Roche Diagnostics, Remel, Olympus, Biorad Laboratories,
Hary Diagnostics and Vista Technology Inc.
May 21-23, 2009, Orange County Convention Center, Florida, USA

- American Association of Clinical Endocrinologists (AACE) 15th annual meeting and clinical congress (Novartis)
Incretins: the missing piece in the type 2 diabetes puzzle
Implications of recent clinical trials: a new perspective on insulin sensitizers
April 28, 2008, Hyatt Regency, Chicago, USA
- Lipid Journal Club, Massachusetts General Hospital, Division of Laboratory Medicine, Department of Pathology
September 2002- January 2006 (weekly), Laboratory Medicine Conference Room, Boston, USA
- Pharmaceutical Science Colloquium, Bouvé College of Pharmacy and Health Sciences, Department of Pharmaceutical Sciences
October 2002- April 2005 (weekly), Snell Library, Boston, USA

PART III:

Format for Bibliography:

Original Articles:

1. Fatty Acid Ethyl Ester Effects on Interleukin-2 Production, Cyclic AMP Synthesis, and Calcium Influx in Human Mononuclear Cells.2006
2. Fatty Acid Ethyl Esters in Human Mononuclear Cells: Production by Endogenous Synthesis Greatly Exceeds the Uptake of Preformed Ethyl Esters.2006
3. Evaluation of a New, Automated Quantitative Factor XIII Assay.2007
4. Induction of Apoptosis and Necrosis in Human Peripheral Blood Mononuclear Cells by Fatty Acid Ethyl Esters.2008
5. Maxillary Fractures in Patients Reviewing Almoujtahed Hospital During the Syrian Crisis.2018
6. Crisis Related Orbit Fractures Distribution and In-Hospital Management at Almoujtahed Hospital.2018
7. Review of mandibular fractures at almoujtahed hospital during the syrian crisis.2018
8. Antibiotic resistance in e.coli strains in samples from almoujtahd hospital.2018
9. Vitamin D3 and Calcium Relation: A Major Dilemma in Recent Times.2019
10. Increased Ratio of Hysterectomies: A Study of The Causes and Prevalence.2019
11. Study of Pus Cultures with Positive Staphylococcus Aureus Culture Results.2019
12. The Effects of Various Treatments on Enterobacter Strains.2019
13. E. coli Resistance to First-Line Treatments: A Burden to Health Care Systems.2019
14. Klebsiella Pneumonia Strains in Sputum Samples and The Efficiency of Different Antibiotics Against Them: A Laboratory Assessment.2019
15. The Disparities Between C-Reactive Protein and Erythrocyte Sedimentation Rate as Markers of Inflammation.2019
16. Study of Erythrocyte Sedimentation Rate and White Blood Cell Count Values in A Clinical Laboratory.2019

17. The Coexistence of Hemoglobin and Serum Iron Levels: Are They Always Synchronized.2019
18. Study of Squamous Cell Carcinomas of The Larynx and The Regional Lymph Nodes Involvement.2019
19. Study of Facial Malignant Skin Tumors in A Randomized Group.2020
20. Evaluation of Nasal Polyposis and its Correlation with Allergic Diseases.2020
21. Analysis of Neck Masses in A Group of Syrian Patients at Almouwasat University Hospital.2020
22. Foreign Body Aspiration: Study of Epidemiological Factors, Site and Type of Foreign Bodies in Children.2020
23. Salivary Gland Tumors: Demographics and Occurrence According to Age and Gender.2020
24. The Increasing Ratio of Cesarean Section Deliveries: Causes and Implications.2020
25. Surgical Thyroid Gland Diseases: Epidemiology and Neck Radiation Effect.2020
26. B-Thalassemia in Patients Reviewing Al-Mouwasat University Hospital in Damascus, Syria.2020
27. Prevalence of Abnormal Pap Smear Results in Syrian Women.2020
28. Study of Acute Bacterial Meningitis: Demographics, Symptoms and Signs.2020
29. Cholesteatoma Effects on Hearing and Ossicles at Al-Mouwasat University Hospital.2020
30. Abdominal Hernias in Adults at a group of Syrian Population.2020
31. Breast Cancer Screening Campaign of 2018 and 2019 at Al-Mouwasat University Hospital in Damascus, Syria.2021
32. Study of Cataract Types and Their Effect on Visual Acuity in a Group of Syrian Population.2021
33. The Use of Platelet Rich Plasma in Bone Regeneration: A Systematic Review.2021
34. Eyeing UP the Pandemic: A Literature Review of The Ocular Manifestations of Covid-19.2022
35. Gauging the learning environment at Damascus University Pharmacy School in Syria using the DREEM questionnaire: A cross-sectional study.2022
36. Evaluation of the Undergraduate Learning Environment at Dental Schools in Syria.2022
37. Revealing the Significant Shortcomings in the Learning Environment at the Three Largest Medical Schools in Syria: What's Next?.2023
38. The Challenging Reality of The Clinical Learning Environment at Damascus University Faculty of Dental Medicine in Syria: a Qualitative Study.2023
39. Evaluation of a workplace assessment method designed to improve self-assessment in operative dentistry: a quasi-experiment. 2023
40. Measuring the clinical learning environment in Syria: Translation of PHEEM into Arabic and proposed modifications. 2023

NIH NCBI (An official website of the United States government):

1. *Ophrys fusca* trnL-trnF intergenic spacer and tRNA-Phe (trnF-GAA) gene, partial sequence; chloroplast
312 bp linear DNA
Accession: OR231540.1

- 2.** *Spiranthes spiralis* trnL-trnF intergenic spacer and tRNA-Phe (trnF-GAA) gene, partial sequence; chloroplast
446 bp linear DNA
Accession: OR231539.1
- 3.** *Ophrys fuciflora* subsp. *bornmuelleri* trnL-trnF intergenic spacer and tRNA-Phe (trnF-GAA) gene, partial sequence; chloroplast
291 bp linear DNA
Accession: OR231538.1
- 4.** *Anacamptis pyramidalis* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
304 bp linear DNA
Accession: OR514371.1
- 5.** *Ophrys ferrum-equinum* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
262 bp linear DNA
Accession: OR514370.1
- 6.** *Platanthera chlorantha* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
263 bp linear DNA
Accession: OR514369.1
- 7.** *Epipactis helleborine* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
406 bp linear DNA
Accession: OR514368.1
- 8.** *Ophrys attica* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
256 bp linear DNA
Accession: OR514367.1
- 9.** *Orchis anatolica* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
313 bp linear DNA
Accession: OR514366.1
- 10.** *Cephalanthera longifolia* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
374 bp linear DNA
Accession: OR514365.1
- 11.** *Anacamptis laxiflora* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
288 bp linear DNA
Accession: OR514364.1
- 12.** *Ophrys sintenisii* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
309 bp linear DNA
Accession: OR514363.1

- 13.** *Anacamptis morio* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
300 bp linear DNA
Accession: OR514362.1
- 14.** *Dactylorhiza iberica* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
300 bp linear DNA
Accession: OR514361.1
- 15.** *Neotinea tridentata* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
300 bp linear DNA
Accession: OR514360.1
- 16.** *Anacamptis collina* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
293 bp linear DNA
Accession: OR514359.1
- 17.** *Orchis italica* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
276 bp linear DNA
Accession: OR514358.1
- 18.** *Limodorum abortivum* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
340 bp linear DNA
Accession: OR514357.1
- 19.** *Dactylorhiza romana* isolate O13 trnL-trnF intergenic spacer, partial sequence; chloroplast
294 bp linear DNA
Accession: OR193407.1
- 20.** *Ophrys argolica* isolate O12 trnL-trnF intergenic spacer, partial sequence; chloroplast
304 bp linear DNA
Accession: OR193406.1
- 21.** *Ophrys lutea* isolate O11 trnL-trnF intergenic spacer, partial sequence; chloroplast
312 bp linear DNA
Accession: OR193405.1
- 22.** *Ophrys attica* isolate O10 trnL-trnF intergenic spacer, partial sequence; chloroplast
258 bp linear DNA
Accession: OR193404.1
- 23.** *Cephalanthera kurdica* isolate O9 trnL-trnF intergenic spacer, partial sequence; chloroplast
372 bp linear DNA
Accession: OR193403.1
- 24.** *Epipactis latifolia* isolate O8 trnL-trnF intergenic spacer, partial sequence; chloroplast
409 bp linear DNA
Accession: OR193402.1
- 25.** *Ophrys scolopax* isolate O7 trnL-trnF intergenic spacer, partial sequence; chloroplast
268 bp linear DNA
Accession: OR193401.1

- 26.** *Anacamptis sancta* isolate O6 trnL-trnF intergenic spacer, partial sequence; chloroplast
293 bp linear DNA
Accession: OR193400.1
- 27.** *Ophrys* sp. O5 trnL-trnF intergenic spacer, partial sequence; chloroplast
308 bp linear DNA
Accession: OR193399.1
- 28.** *Ophrys attica* isolate O4 trnL-trnF intergenic spacer, partial sequence; chloroplast
263 bp linear DNA
Accession: OR193398.1
- 29.** *Serapias vomeracea* isolate O3 trnL-trnF intergenic spacer, partial sequence;
chloroplast
322 bp linear DNA
Accession: OR193397.1
- 30.** *Ophrys fuciflora* isolate O2 trnL-trnF intergenic spacer, partial sequence; chloroplast
242 bp linear DNA
Accession: OR193396.1
- 31.** *Ophrys fuciflora* isolate O1 trnL-trnF intergenic spacer, partial sequence; chloroplast
262 bp linear DNA
Accession: OR193395.1
- 32.** *Aegilops tauschii* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial
sequence; chloroplast
355 bp linear DNA
Accession: OQ944320.1
- 33.** *Aegilops bicornis* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial
sequence; chloroplast
348 bp linear DNA
Accession: OQ701700.1
- 34.** *Aegilops longissima* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial
sequence; chloroplast
348 bp linear DNA
Accession: OQ701699.1
- 35.** *Aegilops umbellulata* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial
sequence; chloroplast
355 bp linear DNA
Accession: OP957417.1
- 36.** *Triticum aestivum* 23S ribosomal RNA, 4.5S ribosomal RNA, and 5S ribosomal RNA
region gene, partial sequence; chloroplast
326 bp linear DNA
Accession: OP262697.1
- 37.** *Rosa x damascena* maturase K (matK) gene, partial cds; chloroplast
532 bp linear DNA
Accession: OR761842.1
- 38.** *Rosa x damascena* trnL-trnF intergenic spacer, partial sequence; chloroplast
423 bp linear DNA
Accession: OR761841.1

- 39.** *Ophrys fuciflora* subsp. *bornmuelleri* voucher O14 ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit gene, partial cds; chloroplast
545 bp linear DNA
Accession: OR727283.1
- 40.** *Aegilops comosa* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
355 bp linear DNA
Accession: OR597600.1
- 41.** *Aegilops markgrafii* trnL-trnF intergenic spacer and tRNA-Phe (trnF) gene, partial sequence; chloroplast
355 bp linear DNA
Accession: OR597599.1
- 42.** *Himantoglossum affine* trnL-trnF intergenic spacer and tRNA-Phe gene, partial sequence; chloroplast
289 bp linear DNA
Accession: OR545541.1
- 43.** *Amblyopyrum muticum* trnL-trnF intergenic spacer, partial sequence; chloroplast
372 bp linear DNA
Accession: OR420983.1
- 44.** *Triticum aestivum* trnL-trnF intergenic spacer, partial sequence; chloroplast
368 bp linear DNA
Accession: OR420982.1

Thesis (M.S. level):

Alhomsy K. Acute Lymphocytic Leukemia in 9 years old girl.
Northeastern University; Boston, USA, 2002

Conference Proceedings:

Alhomsy K, Laposata M. Effects of Fatty Acid Ethyl Esters on Human Mononuclear Cell Morphology, Activation and Viability
Pharmaceutical science showcase, Northeastern University, Boston, USA, 2005

Dissertation (Ph.D. level):

Alhomsy K. Effects of Fatty Acid Ethyl Esters on Human Mononuclear Cell Morphology, Activation and Viability
Northeastern University; Boston, USA, 2005